468 related articles for article (PubMed ID: 26581710)
21. Correlation between serum anti-TSH receptor autoantibodies (TRAbs) and the clinical feature of Graves' orbitopathy.
Nicolì F; Lanzolla G; Mantuano M; Ionni I; Mazzi B; Leo M; Sframeli A; Posarelli C; Maglionico MN; Figus M; Nardi M; Marcocci C; Marinò M
J Endocrinol Invest; 2021 Mar; 44(3):581-585. PubMed ID: 32648002
[TBL] [Abstract][Full Text] [Related]
22. Relationship between longitudinal behaviour of some markers of eye autoimmunity and changes in ocular findings in patients with Graves' ophthalmopathy receiving corticosteroid therapy.
De Bellis A; Bizzarro A; Conte M; Coronella C; Solimeno S; Perrino S; Sansone D; Guaglione M; Wall JR; Bellastella A
Clin Endocrinol (Oxf); 2003 Sep; 59(3):388-95. PubMed ID: 12919164
[TBL] [Abstract][Full Text] [Related]
23. IGF1 deficiency in newly diagnosed Graves' disease patients.
Martin S; Sirbu A; Betivoiu M; Florea S; Barbu C; Fica S
Hormones (Athens); 2015; 14(4):651-9. PubMed ID: 26188228
[TBL] [Abstract][Full Text] [Related]
24. Correlation of orbital muscle changes evaluated by magnetic resonance imaging and thyroid-stimulating antibody in patients with Graves' ophthalmopathy.
Nishikawa M; Yoshimura M; Toyoda N; Masaki H; Yonemoto T; Gondou A; Kato T; Kurokawa H; Furumura T; Inada M
Acta Endocrinol (Copenh); 1993 Sep; 129(3):213-9. PubMed ID: 8105634
[TBL] [Abstract][Full Text] [Related]
25. Clinical relevance of thyroid-stimulating immunoglobulins in graves' ophthalmopathy.
Ponto KA; Kanitz M; Olivo PD; Pitz S; Pfeiffer N; Kahaly GJ
Ophthalmology; 2011 Nov; 118(11):2279-85. PubMed ID: 21684605
[TBL] [Abstract][Full Text] [Related]
26. Graves' ophthalmopathy in the absence of elevated free thyroxine and triiodothyronine levels: prevalence, natural history, and thyrotropin receptor antibody levels.
Khoo DH; Eng PH; Ho SC; Tai ES; Morgenthaler NG; Seah LL; Fong KS; Chee SP; Choo CT; Aw SE
Thyroid; 2000 Dec; 10(12):1093-100. PubMed ID: 11201855
[TBL] [Abstract][Full Text] [Related]
27. Measuring TSH receptor antibody to influence treatment choices in Graves' disease.
Hesarghatta Shyamasunder A; Abraham P
Clin Endocrinol (Oxf); 2017 May; 86(5):652-657. PubMed ID: 28295509
[TBL] [Abstract][Full Text] [Related]
28. Thyrotropin receptor antibodies in hypothyroid Graves' disease.
Kasagi K; Hidaka A; Nakamura H; Takeuchi R; Misaki T; Iida Y; Konishi J
J Clin Endocrinol Metab; 1993 Feb; 76(2):504-8. PubMed ID: 8094394
[TBL] [Abstract][Full Text] [Related]
29. Serum thyroglobulin is associated with orbitopathy in Graves' disease.
Khamisi S; Lundqvist M; Emadi P; Almby K; Ljunggren Ö; Karlsson FA
J Endocrinol Invest; 2021 Sep; 44(9):1905-1911. PubMed ID: 33515213
[TBL] [Abstract][Full Text] [Related]
30. [Predictive value of thyrotropin receptor antibodies using the second generation TRAb human assay after radioiodine treatment in Graves' disease].
Zöphel K; Wunderlich G; Kopprasch C; Koch R; Franke WG; Kotzerke J
Nuklearmedizin; 2003; 42(2):63-70. PubMed ID: 12695788
[TBL] [Abstract][Full Text] [Related]
31. CD4+ T cells and the Th1/Th2 imbalance are implicated in the pathogenesis of Graves' ophthalmopathy.
Xia N; Zhou S; Liang Y; Xiao C; Shen H; Pan H; Deng H; Wang N; Li QQ
Int J Mol Med; 2006 May; 17(5):911-6. PubMed ID: 16596280
[TBL] [Abstract][Full Text] [Related]
32. Measurement of anti-TSH receptor antibodies: what is the correct cut-off value?
Smit MA; van Kinschot CMJ; van der Linden J; van Noord C; Kos S
Neth J Med; 2020 Mar; 78(2):55-63. PubMed ID: 32332174
[TBL] [Abstract][Full Text] [Related]
33. Performance of a third-generation TSH-receptor antibody in a UK clinic.
Theodoraki A; Jones G; Parker J; Woolman E; Martin N; Perera S; Thomas M; Bunn C; Khoo B; Bouloux PM; Vanderpump MP
Clin Endocrinol (Oxf); 2011 Jul; 75(1):127-33. PubMed ID: 21521291
[TBL] [Abstract][Full Text] [Related]
34. Serum concentrations of HGF and IL-8 in patients with active Graves' orbitopathy before and after methylprednisolone therapy.
Nowak M; Siemińska L; Karpe J; Marek B; Kos-Kudła B; Kajdaniuk D
J Endocrinol Invest; 2016 Jan; 39(1):63-72. PubMed ID: 26062519
[TBL] [Abstract][Full Text] [Related]
35. Prognostic significance of thyroid-stimulating hormone receptor antibodies in moderate-to-severe graves' orbitopathy.
Park J; Kim J; Kim SS; Choi HY
Front Endocrinol (Lausanne); 2023; 14():1153312. PubMed ID: 37223049
[TBL] [Abstract][Full Text] [Related]
36. Serum antibodies against the insulin-like growth factor-1 receptor (IGF-1R) in Graves' disease and Graves' orbitopathy.
Marinò M; Rotondo Dottore G; Ionni I; Lanzolla G; Sabini E; Ricci D; Sframeli A; Mazzi B; Menconi F; Latrofa F; Vitti P; Marcocci C; Chiovato L
J Endocrinol Invest; 2019 Apr; 42(4):471-480. PubMed ID: 30132285
[TBL] [Abstract][Full Text] [Related]
37. Continued suppression of serum TSH level may be attributed to TSH receptor antibody activity as well as the severity of thyrotoxicosis and the time to recovery of thyroid hormone in treated euthyroid Graves' patients.
Chung YJ; Lee BW; Kim JY; Jung JH; Min YK; Lee MS; Lee MK; Kim KW; Chung JH
Thyroid; 2006 Dec; 16(12):1251-7. PubMed ID: 17199435
[TBL] [Abstract][Full Text] [Related]
38. Usefulness of TSH receptor antibodies as biomarkers for Graves' ophthalmopathy: a systematic review.
Seo S; Sánchez Robledo M
J Endocrinol Invest; 2018 Dec; 41(12):1457-1468. PubMed ID: 30194634
[TBL] [Abstract][Full Text] [Related]
39. Total thyroidectomy for the treatment of recurrent graves' disease with ophthalmopathy.
Nart A; Uslu A; Aykas A; Yuzbasioglu F; Dogan M; Demirtas O; Simsek C
Asian J Surg; 2008 Jul; 31(3):115-8. PubMed ID: 18658008
[TBL] [Abstract][Full Text] [Related]
40. Partial prediction of postpartum Graves' thyrotoxicosis by sensitive bioassay for thyroid-stimulating antibody measured in early pregnancy.
Ide A; Amino N; Nishihara E; Kudo T; Ito M; Kimura Y; Tatsumi N; Yamazaki M; Miyauchi A
Endocr J; 2016 Oct; 63(10):929-932. PubMed ID: 27432817
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
